Eli Lilly, who is facing increasing scrutiny in the US Congress over large increases in the list price of Humalog insulin, said the price it was paid for Humalog insulin fell by 8.1 percent during the previous five years after accounting for rebates and discounts, The Wall Street Journal reported Sunday.
According to Lilly, the net price for the product fell to an average of $135 a patient a month in 2018, from $147 in 2014.
During the same period, the product's average list price rose 51.9 percent to $594 per patient monthly.
This year, House and Senate committees sent letters to Lilly, Sanofi and Novo Nordisk, seeking information on the rising cost of the company's insulins and details about rebates paid to drug-supply chain companies.
A Lilly spokesman said the Humalog pricing information "will provide greater transparency into the significant rebates and discounts we provide to payers and other supply chain entities for this important medicine."
To read more NewsPoints articles, click here.